TP53 and non-small cell lung carcinoma: In contrast to that, a prospective analysis reported by Peng Song has proved that patients who obtained durable benefit by immunotherapy in NSCLC had higher rates of PTEN mutation and TP53 + PTEN co-mutation, suggesting that patients with these gene mutations may achieve positive effect from immunotherapy.